Coexpression of the Type 2 Diabetes Susceptibility Gene Variants KCNJ11 E23K and ABCC8 S1369A Alter the ATP and Sulfonylurea Sensitivities of the ATP-Sensitive K+ Channel by Hamming, Kevin S.C. et al.
Coexpression of the Type 2 Diabetes Susceptibility Gene
Variants KCNJ11 E23K and ABCC8 S1369A Alter the
ATP and Sulfonylurea Sensitivities of the ATP-Sensitive
K
 Channel
Kevin S.C. Hamming,
1 Daniel Soliman,
1 Laura C. Matemisz,
1 Omid Niazi,
1 Yiqiao Lang,
1
Anna L. Gloyn,
2 and Peter E. Light
1
OBJECTIVE—In the pancreatic -cell, ATP-sensitive K
 (KATP)
channels couple metabolism with excitability and consist of
Kir6.2 and SUR1 subunits encoded by KCNJ11 and ABCC8,
respectively. Sulfonylureas, which inhibit the KATP channel, are
used to treat type 2 diabetes. Rare activating mutations cause
neonatal diabetes, whereas the common variants, E23K in
KCNJ11 and S1369A in ABCC8, are in strong linkage disequilib-
rium, constituting a haplotype that predisposes to type 2
diabetes. To date it has not been possible to establish which of
these represents the etiological variant, and functional studies
are inconsistent. Furthermore, there have been no studies of the
S1369A variant or the combined effect of the two on KATP
channel function.
RESEARCH DESIGN AND METHODS—The patch-clamp
technique was used to study the nucleotide sensitivity and
sulfonylurea inhibition of recombinant human KATP channels
containing either the K23/A1369 or E23/S1369 variants.
RESULTS—ATP sensitivity of the KATP channel was decreased
in the K23/A1369 variant (half-maximal inhibitory concentration
[IC50]  8.0 vs. 2.5 mol/l for the E23/S1369 variant), although
there was no difference in ADP sensitivity. The K23/A1369 variant
also displayed increased inhibition by gliclazide, an A-site sulfo-
nylurea drug (IC50  52.7 vs. 188.7 nmol/l for the E23/S1369
variant), but not by glibenclamide (AB site) or repaglinide (B
site).
CONCLUSIONS—Our ﬁndings indicate that the common K23/
A1369 variant KATP channel displays decreased ATP inhibition
that may contribute to the observed increased risk for type 2
diabetes. Moreover, the increased sensitivity of the K23/A1369
variant to the A-site sulfonylurea drug gliclazide may provide a
pharmacogenomic therapeutic approach for patients with type 2
diabetes who are homozygous for both risk alleles. Diabetes 58:
2419–2424, 2009
R
ecent large-scale human genetic studies have
made dramatic progress in identifying type 2
diabetes susceptibility genes, increasing the
list from three genes (PPARG, KCNJ11, and
TCF7L2) to nearly 20 genes in the last 2 years (1).
Despite this rapid progress, what the precise causal
variant is and how the variant increases susceptibility to
type 2 diabetes is still unknown in the majority of cases.
Even the widely accepted type 2 diabetes susceptibility
gene KCNJ11 has not yet had the mutational mecha-
nisms fully elucidated.
In pancreatic -cells and the central nervous system,
ATP-sensitive K
 (KATP) channels are composed of the
Kir6.2 and SUR1 subunits encoded by the KCNJ11 and
ABCC8 genes, respectively. KATP channels act as key
transducers of metabolic signals to excitability in many
cell types including the regulation of insulin secretion (2),
and the KATP channel is the target for commonly used
antidiabetic sulfonylurea drugs (3). The importance of the
KATP channel in diabetes is highlighted by the fact that rare
heterozygous activating mutations in KCNJ11 or ABCC8
cause diabetes with varying clinical severities (4–6).
One of the ﬁrst reproducibly associated type 2 diabetes
susceptibility signals identiﬁed was the common E23K
(rs5219) variant of KCNJ11 (7,8). Functional studies were
subsequently performed, but the results were inconsistent
(9–11). Moreover, ﬁne mapping in the region demon-
strated the difﬁculty in identifying the causal variant when
a second nonsynonymous (S1369A; rs757110) variant in
the neighboring ABCC8 gene was shown to be in complete
linkage disequilibrium with the E23K KCNJ11 variant (12).
The implications of this were that 1) it was not possible
from the genetic evidence to say which variant is actually
the etiological variant and 2) individuals who carried the K
risk allele of the E23K variant also carried the A risk allele
of the S1369A variant. Consequently, functional studies to
investigate the mutational mechanism need to include
both variants.
RESEARCH DESIGN AND METHODS
Molecular biology. The human KATP channel Kir6.2 and SUR1 subunit clones
were kindly provided by J. Bryan (Paciﬁc Northwest Diabetes Research
Institute, Seattle, WA). The E23K and S1369A variants were introduced into
the KCNJ11 and ABCC8 cDNAs, respectively, using site-directed mutagenesis
(QuikChange; Stratagene).
Cell culture, transfection, and electrophysiology. Cultured tsA201 cells
were transfected with the KCNJ11 and ABCC8 clones using the calcium
phosphate precipitation technique (13). Transfected cells were identiﬁed
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cent protein plasmid (Life Technologies, Gaithersburg, MD). Macroscopic
KATP channel recordings were then performed 48–72 h after transfection.
The inside-out patch-clamp technique was used to measure macroscopic
KATP channel currents in transfected tsA201 cells as described in detail
previously (13).
Experimental compounds. MgATP and MgADP (Sigma, Oakville, Ontario)
were prepared as 10 mmol/l stocks in ddH2O immediately prior to use.
Glibenclamide, gliclazide, and repaglinide (Sigma, Oakville, Ontario) were
prepared as 10 mmol/l stocks in DMSO and stored at 20°C. DMSO concen-
tration was maintained at 0.1% in all experimental solutions.
Statistical analysis. Macroscopic KATP channel currents were normalized
and expressed as changes in current relative to control (i.e., normalized KATP
channel current  Itest/Icontrol). Single-channel analysis was performed using
pClamp v. 10.0 software (Axon Instruments). Statistical signiﬁcance was
assessed using the unpaired Student’s t test or one-way ANOVA with a
Bonnferoni post hoc test. P  0.05 was considered statistically signiﬁcant.
Data are expressed as means  SE.
RESULTS
Residue S1369 is proximal to the second nucleotide-
binding domain in SUR1, which forms part of the MgATP-
and MgADP-sensing region in SUR1 that is a key regulator
of KATP channel activity and, hence, insulin secretion
(3,14). However, the direct effects of the K23/A1369 variant
on human KATP channel nucleotide sensitivities have not
been investigated.
Therefore, to gain insights into the nucleotide regulation
of K23/A1369 variant KATP channel activity, the MgATP
and MgADP sensitivities of recombinant human KATP
channels containing either the K23/A1369 or the E23/S1369
variants were compared. Our results indicate that the
K23/A1369 variant decreases the MgATP sensitivity of the
KATP channel (half-maximal inhibitory concentration
FIG. 1. The K23/A1369 variant KATP channel exhibits decreased sensitivity to
MgATP. A: Representative macroscopic current recordings of recombinant
human KATP channel activity at different MgATP concentrations. B: MgATP
inhibition response curves illustrating that the K23/A1369 variant is less
sensitive to MgATP inhibition than the E23/S1369 variant. n  3–11 patches
per concentration. Extrapolation of the curves to millimolar physiological
MgATP levels (inset). C and D: Representative single-channel recordings of
E23/S1369 and K23/A1369 variant KATP channels at 0 and 1 mmol/l MgATP (o,
open state; c, closed state). Single-channel unitary current amplitude was not
different between the variants. E and F: Grouped open probability (Po) data
from 3–6 patches (containing 1–4 KATP channels per patch) showing no
difference in open probability at 0 mmol/l MgATP but a signiﬁcantly increased
open probability in the K23/A1369 variant KATP channels at 1 mmol/l MgATP.
G: MgATP inhibition curves from quasi-heterologous KATP channels contain-
ing either the K23/S1369 or E23/A1369 variant combinations (n  3–8 patches
per MgATP concentration in each group). Dashed line, MgATP inhibition
curve for the wild-type E23/S1369 variant replotted from panel B.* P < 0.05.
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variant, P  0.05; Fig. 1A and B). Extrapolation of the
MgATP concentration-inhibition curve to physiological
millimolar intracellular MgATP levels (1–5 mmol/l) pre-
dicted that the shift in IC50 may result in the K23/A1369
variant remaining slightly more active compared with the
E23/S1369 variant (Fig. 1B, inset). Subsequent single-
channel experiments conﬁrmed this prediction with the
open probability of the K23/A1369 variant being signiﬁ-
cantly greater than the E23/S1369 variant at 1 mmol/l
MgATP but not at 0 mmol/l MgATP (Fig. 1C–F). To
determine whether one or both of the K23 or A1369
variants account for the reduced MgATP sensitivity,
MgATP concentration-inhibition curves were constructed
from quasi-heterologous KATP channels expressing either
E23/A1369 or K23/S1369. These results indicate that it is
the ABCC8 A1369 variant, not the KCNJ11 K23 variant,
that confers the reduced MgATP sensitivity to the KATP
channel complex (IC50  8.2  1.6 vs. 3.2  0.3 mol/l for
E23/A1369 vs. K23/S1369, respectively; Fig. 1G).
The intracellular ATP-to-ADP ratio is a major determi-
nant of KATP channel activity because MgADP antagonizes
the inhibitory effects of ATP, and rare monogenic muta-
tions in ABCC8 that reduce MgADP antagonism decrease
channel activity and cause hyperinsulinism (14). Accord-
ingly, the stimulatory effects of varying concentrations of
MgADP were tested in the presence of 0.1 mmol/l MgATP.
However, no signiﬁcant differences were observed be-
tween the E23/S1369 and K23/A1369 KATP channel variants
(Fig. 2A and B).
The KATP channel is the molecular target for sulfonyl-
urea and glinide drugs that are commonly used to stimu-
late insulin secretion in type 2 diabetes. Interestingly,
recent clinical data suggest that diabetic patients who are
homozygous for the A1369 risk allele (A/A) are more
responsive to gliclazide therapy (15). However, it is un-
known whether this is due to a direct effect on the KATP
channel because the inhibitory proﬁle of gliclazide and
other drugs on the K23/A1369 variant KATP channel has not
been determined.
Sulfonylurea and glinide drugs can be grouped accord-
ing to their binding to the A, B, or AB sites in the KATP
channel complex (3,16,17). The A site is located close to
SUR1 transmembrane segments 14–16, and the S1237Y
mutation in this region (Fig. 3A) abolishes A-site drug
inhibition (18). Two regions of the KATP channel contrib-
ute to the B site: the intracellular loop between SUR1
transmembrane segments 5 and 6 and the NH2-terminus of
Kir6.2 (16) (Fig. 3A). Figure 3B shows the structures of the
glinide repaglinide (B site) and the sulfonylureas gliben-
clamide (AB site) and gliclazide (A site). The SUR1 residue
S1369 is in close proximity to the A site (Fig. 3A).
Therefore, the A1369 variant may contribute to altered
KATP channel sensitivity to A-site drugs such as gliclazide.
Gliclazide (300 nmol/l) inhibited the K23/A1369 variant to
a greater extent than the E23/S1369 variant (Fig. 3C and
D). Construction of gliclazide concentration-inhibition
curves revealed that the K23/A1369 variant was 3.5-fold
more sensitive to gliclazide inhibition than the E23/S1369
variant (IC50 52.7  11.1 vs. 188.7  32.6 nmol/l, respec-
tively; Fig. 3E). Because the K23/A1369 KATP channel
variant may also alter the potency of other drug classes,
the effects of glibenclamide (AB site) and repaglinide (B
site) were tested. In direct contrast to the observed effects
of gliclazide, no signiﬁcant differences in either gliben-
clamide (3 nmol/l) or repaglinide (10 nmol/l) inhibition
were found between the K23/A1369 and E23/S1369 variant
KATP channels (Fig. 3F). It is possible that gliclazide
inhibition may be affected by intracellular MgADP. In the
presence of 0.1 mmol/l MgATP and 0.1 mmol/l MgADP, 300
nmol/l gliclazide still elicited a signiﬁcantly greater inhibi-
tion of the K23/A1369 KATP channel variant than the
E23/S1369 variant (Fig. 4A–C).
The data presented indicate that the K23/A1369 variant
KATP channel is more sensitive to inhibition by gliclazide
but not glibenclamide or repaglinide. However, the relative
individual contributions of the ABCC8 A1369 or KCNJ11
K23 variants to gliclazide sensitivity have not been deter-
mined. Therefore, gliclazide inhibition was measured in
quasi-heterologous KATP channels containing either the
E23/A1369 or K23/S1369 variant combinations. E23/A1369
KATP channels displayed a signiﬁcantly greater gliclazide
inhibition than K23/S1369 KATP channels, which was sim-
ilar in magnitude to that observed in the increased diabe-
tes risk for the K23/A1369 variant KATP channel (Fig.
4D–F). Results from these experiments indicate that the
enhanced gliclazide sensitivity in the K23/A1369 KATP
FIG. 2. A: Representative macroscopic current recordings of the MgADP stimulatory effects of 0.1 mmol/l MgADP in the presence of 0.1 mmol/l
MgATP. B: Concentration response curves for the stimulatory effects of increasing MgADP concentrations in the presence of 0.1 mmol/l MgATP.
Results show no signiﬁcant differences in MgADP stimulation between the E23/S1369 and K23/A1369 haplotypes across a range of MgADP
concentrations (P > 0.05). n  3–10 patches per group.
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and not the KCNJ11 K23 variant.
DISCUSSION
Previous studies have investigated the properties of KATP
channels containing the KCNJ11 K23 variant (9–11), al-
though 95% of people with two copies of K23 are also
homozygous for A1369 (12). Therefore, this study is the
ﬁrst to document the properties and pharmacology of the
most commonly found KATP channel variant that contains
both K23 and A1369 risk alleles. Our study reveals novel
differences in both the MgATP and sulfonylurea sensitivity
of this variant KATP channel.
With respect to MgATP sensitivity, the moderate right-
ward shift in IC50 for MgATP inhibition seen in the
K23/A1369 variant results in increased basal KATP channel
activity at physiological MgATP levels. In direct contrast
to the rare monogenic KATP channel mutations that cause
neonatal diabetes and drastically decreased MgATP inhi-
bition, a modest increase in K23/A1369 variant KATP
channel activity may predispose to type 2 diabetes in
combination with other factors. Indeed, we have previ-
ously shown that the K23 variant increases the sensitivity
of the KATP channel to activation by intracellular acyl
CoAs (11,13). KATP channels encoded by the KCNJ11 and
ABCC8 genes are also expressed in pancreatic 	-cells and
hypothalamic neurons that centrally regulate glucose/
energy homeostasis (19). Therefore, it is plausible that
subtle increases in the activity of K23/A1369 variant KATP
channels may alter glucagon secretion and centrally me-
diated glucose homeostasis, further contributing to the
development of type 2 diabetes.
The molecular mechanism for the reduced ATP inhibi-
tion observed in KATP channels expressing the K23/A1369
variant proteins is of importance. Free ATP inhibits KATP
channel activity via binding to the Kir6.2 subunit, whereas,
paradoxically, MgATP can activate the channel via intrin-
sic MgATPase activity of the nucleotide-binding folds in
SUR1, resulting in production of MgADP that may stimu-
late channel activity (2). In direct contrast to a previous
study on the KCNJ11 K23 variant (20), our results indicate
that the stimulatory effects of MgADP are unaltered in the
K23/A1369 variant KATP channel, suggesting that the mo-
lecular mechanism for decreased ATP inhibition does not
involve altered MgADP sensitivity per se. Our results also
show that the observed decrease in ATP inhibition in the
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E23/S1369, respectively). n  3–12 patches per gliclazide concentration. F: Grouped data demon-
strating that the K23/A1369 variant is signiﬁcantly more sensitive to inhibition by gliclazide but
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of the ABCC8 A1369 risk allele reducing ATP inhibition
(9), perhaps via mild increases in the intrinsic KATP
channel MgATPase activity. Indeed, several rare heterozy-
gous mutations in ABCC8 that cause neonatal diabetes
(R1380L and R1380C) act by increasing MgATPase ac-
tivity (21). Interestingly, the location of the ABCC8
S1369 residue is in close proximity to the MgATPase
catalytic site and residue R1380 in the SUR1 nucleotide-
binding fold 2 (22).
Sulfonylurea and glinide drugs that inhibit KATP chan-
nels are in extensive clinical use to stimulate insulin
secretion in patients with type 2 diabetes (3). Gliben-
clamide is an AB-site ligand and is the most widely used
sulfonylurea, whereas gliclazide is an A-site ligand selec-
tively inhibiting KATP channels containing the SUR1 iso-
form, potentially mitigating any cardiotoxicity that has
been associated with glibenclamide monotherapy (23,24).
Our results indicate that the K23/A1369 variant KATP
channel is 3.5-fold more sensitive to gliclazide. These
ﬁndings are the ﬁrst to directly demonstrate altered sulfo-
nylurea sensitivities of the K23/A1369 variant KATP channel
and identify the ABCC8 A1369 risk allele as conferring
this effect upon the K23/A1369 variant KATP channel.
These results provide a molecular mechanism for the
increase in clinical efﬁcacy of gliclazide in subjects with
type 2 diabetes who are homozygous for the A1369 allele
variant (15).
In conclusion, this study provides the ﬁrst evidence that
the ABCC8 S1369A variant alters the properties of the
KATP channel that may contribute to the increased risk for
type 2 diabetes associated with the K23/A1369 risk haplo-
type. The increased gliclazide sensitivity observed in the
K23/A1369 variant KATP channel (afforded by the ABCC8
A1369 risk allele) encourages the study of sulfonylurea
pharmacogenomics in larger cohorts and supports a ratio-
nale for tailoring pharmacotherapy in the 
20% of type 2
diabetic patients who carry two copies of these risk
alleles.
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